#Germany #biopharmaceuticals #Frankfurt #Kexing Biopharm #CPHI Frankfurt

Kexing Biopharm's Global Strategy Unveiled at CPHI Frankfurt 2025

Kexing Biopharm participated in CPHI Frankfurt 2025, one of the most influential pharmaceutical trade shows worldwide, from October 28 to 30, 2025. The event served as a vital platform for Kexing to showcase its robust product portfolio and international marketing solutions to potential partners across various global markets.

During this significant event, Kexing's international team engaged in productive discussions with industry representatives from multiple countries. The conversations covered critical areas such as product registration, market access, and local collaboration strategies. In addition, Kexing Biopharm took the opportunity to highlight its end-to-end pharmaceutical capabilities, providing a comprehensive range from Active Pharmaceutical Ingredients (APIs) to finished dosage forms, all upheld by systems that adhere to international quality and regulatory standards.

CPHI Frankfurt not only enables companies to present their products and services but also serves as a crucial bridge for sharing industry information and integrating resources. In this spirit, Kexing's team actively visited competitor booths, scheduled meetings with customers, and exchanged insights with industry partners regarding global trends in the pharmaceutical sector and the dynamics of overseas market policies. This engagement proved invaluable, allowing Kexing to optimize its future overseas expansion strategies while identifying potential clients.

In recent years, Kexing Biopharm has advanced its strategy of 'Global Selection + Global Coverage', identifying and introducing high-quality products in oncology, autoimmune diseases, metabolism, and specialized therapeutic areas. Through this internationalization model, Kexing aspires to accelerate the commercialization of high-quality Chinese medicines on a global scale.

Looking ahead, Kexing Biopharm continues to dedicate itself to expanding its presence in global markets by fostering open collaboration, executing professional activities, and adopting a patient-centric approach. The goal is to ensure that patients in more regions have access to accessible and quality healthcare solutions.

Kexing Biopharm (stock code 688136.SH) is a multinational biopharmaceutical company focused on the research and development, production, and sale of innovative medicines across various modalities, including recombinant proteins, antibodies, and cellular/gene therapies. By building advanced technology platforms that enhance the development of new targeted therapies and drug delivery systems, Kexing aims to address unmet clinical needs in the fields of oncology, autoimmune diseases, and antiviral treatments. This commitment can significantly and positively impact patients' lives.

By adhering to a platform development model driven by the dual engine of innovation and internationalization, Kexing strives to become a global leader in high-quality biopharmaceutical products that improve patient health worldwide.